Literature DB >> 33515332

Botulinum toxin dosing in arm muscles: contextual factors.

Dirk Dressler1, Bruno Kopp2, Fereshte Adib Saberi3.   

Abstract

Botulinum toxin (BT) has been successfully used for many years to treat various muscle hyperactivity disorders including dystonia and spasticity. Its dosing is guided by dosing tables describing target muscles and dose ranges. To refine the BT dosing, we wanted to analyse how contextual factors may influence the injector's final dosing decision.In a retrospective review of real-life data of 1170 BT treatments, we studied the influence of various contextual factors on the BT doses in 21 arm muscles of 252 patients receiving BT therapy for different muscle hyperactivity disorders.We found that BT arm doses are significantly higher in treatment of spasticity than in treatment of dystonia. We also found that spontaneous arm dystonia requires higher BT doses in a proximal application pattern, whereas task specific writer's cramp requires considerably reduced BT doses with a distal application pattern. Injections of non-arm muscles influence the BT dosing in arm muscles only marginally.Our study demonstrates that BT dosing does not only depend on the particularities of the individual target muscle injected, such as its volume and its static or phasic function. BT dosing and its application pattern rather depend on additional contextual factors such as the aetiology and pathophysiology of the muscle hyperactivity treated. These contextual factors need to be included in dosing tables and may improve the outcome of BT therapy.

Entities:  

Keywords:  Botulinum toxin; Contextual factors; Dosing tables; Dystonia; Spasticity; Therapy; Writer's cramp

Year:  2021        PMID: 33515332      PMCID: PMC7969489          DOI: 10.1007/s00702-021-02307-1

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  8 in total

1.  Measuring the potency labelling of onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin (®)) in an LD50 assay.

Authors:  Dirk Dressler; Gerd Mander; Klaus Fink
Journal:  J Neural Transm (Vienna)       Date:  2011-10-05       Impact factor: 3.575

2.  Comparing incobotulinumtoxinA (Xeomin®) and onabotulinumtoxinA (Botox®): identical potency labelling in the hemidiaphragm assay.

Authors:  Dirk Dressler; Lizhen Pan; Hans Bigalke
Journal:  J Neural Transm (Vienna)       Date:  2018-06-26       Impact factor: 3.575

3.  Comparing Botox and Xeomin for axillar hyperhidrosis.

Authors:  Dirk Dressler
Journal:  J Neural Transm (Vienna)       Date:  2010-02-09       Impact factor: 3.575

Review 4.  Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force.

Authors:  Dirk Dressler; Roongroj Bhidayasiri; Saeed Bohlega; Abderrahmane Chahidi; Tae Mo Chung; Markus Ebke; L Jorge Jacinto; Ryuji Kaji; Serdar Koçer; Petr Kanovsky; Federico Micheli; Olga Orlova; Sebastian Paus; Zvezdan Pirtosek; Maja Relja; Raymond L Rosales; José Alberto Sagástegui-Rodríguez; Paul W Schoenle; Gholam Ali Shahidi; Sofia Timerbaeva; Uwe Walter; Fereshte Adib Saberi
Journal:  J Neurol       Date:  2016-10-27       Impact factor: 4.849

5.  Routine use of Xeomin in patients previously treated with Botox: long term results.

Authors:  D Dressler
Journal:  Eur J Neurol       Date:  2009-12       Impact factor: 6.089

6.  Safety aspects of incobotulinumtoxinA high-dose therapy.

Authors:  Dirk Dressler; Fereshte Adib Saberi; Katja Kollewe; Christoph Schrader
Journal:  J Neural Transm (Vienna)       Date:  2014-07-17       Impact factor: 3.575

7.  Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The TOWER study.

Authors:  Jörg Wissel; Djamel Bensmail; Joaquim J Ferreira; Franco Molteni; Lalith Satkunam; Susana Moraleda; Tiina Rekand; John McGuire; Astrid Scheschonka; Birgit Flatau-Baqué; Olivier Simon; Edward T J Rochford; Dirk Dressler; David M Simpson
Journal:  Neurology       Date:  2017-03-10       Impact factor: 9.910

8.  Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin (®)).

Authors:  Dirk Dressler; Pawel Tacik; Fereshte Adib Saberi
Journal:  J Neural Transm (Vienna)       Date:  2013-08-04       Impact factor: 3.575

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.